---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000012"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:21:38.729256+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rallybio cuts 45% of workforce, extends cash runway to mid-2026

## Summary
- Workforce reduction of 45% (19 positions); expects ~$3.3M in severance charges.
- Preliminary cash, equivalents and marketable securities of $109.9M as of Dec 31, 2023.
- Prioritizes Phase 2-ready programs RLYB212 (FNAIT) and RLYB116 (C5 inhibitor).
- Cash runway extended into mid-2026; preclinical programs seek alternative funding.
- RLYB212 Phase 2 update with EMA expected H1 2024; Phase 2 initiation in H2 2024.

## SEC filing metadata
- accession: 0001739410-24-000012
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/0001739410-24-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/rlyb-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000012
- JSON: https://secwatch.observer/filing/0001739410-24-000012.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000012.txt

## Key facts
- Restructurings & Charges
  Rallybio Corp announced a restructuring with charges of approximately $3.3 million affecting Rallybio (approximately 45% of its current positions).
  - Type: restructuring
  - Charge: approximately $3.3 million
  - Affected area: Rallybio
  - Headcount: approximately 45% of its current positions
  source text: On February 6, 2024, Rallybio announced the prioritization of its portfolio and a workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. As part of this effort, Rallybio will eliminate approximately 45% of its current positions. As a result of these actions, Rallybio expects to incur charges of approximately $3.3 million, excluding share-based compensation expense.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000012/0001739410-24-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.